Clovis Oncology, execs to pay $20 million to settle SEC charges

U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

https://ift.tt/2NS7K85 support@endlesssupplies.biz (Endless Supplies .Biz) September 18, 2018 at 01:52PM